#最小單位貼紙

Induction of remission in patients with acute promyelocytic leukemia (APL), French American British (FAB) classification M3 (including the M3 variant) characterized by t(15;17) translocation and/or PML/RARα gene presence.

Tretinoin appears to bind one or more nuclear receptors and decreases proliferation and induces differentiation of APL cells; initially produces maturation of primitive promyelocytes and repopulates the marrow and peripheral blood with normal hematopoietic cells to achieve complete remission.

Absorption: well absorbed; Protein binding: >95%, predominantly to albumin. Metabolism: hepatic via CYP; primary metabolite: 4-oxo-all-trans-retinoic acid; displays autometabolism. Terminal elimination half-life:: parent drug: 0.5-2 hours. Time to peak: 1-2 hours. Excretion: Urine (63%), feces (30%).

Hypersensitivity to retinoids, pregnancy, lactation.

X

unknown/ not recommended.

Haemorrhage, reversible hypercholesterolemia and/or hypertriglyceridemia, acidosis, hypothermia, pseudotumour cerebri, infection, dizziness, paresthesias, anxiety, dryness of skin and mucous membranes, nausea, vomiting, GI haemorrhage, mucositis, decreased appetite, rash, pruritus, increased sweating, alopecia, bone pain, peripheral oedema, renal insufficiency, earache, visual disturbances, neurotoxicity.

Acute promyelocytic leukaemia 45 mg/m2 /day in 2 divided doses, continue treatment until 30 days after complete remission or 90 days of treatment given, whichever occurs 1st.

For renal impaired patients: 25 mg/m2/day

For hepatic impaired patients: 25 mg/m2/day